PLYMOUTH
MEETING, Pa., July 1, 2024
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company
focused on developing and commercializing DNA medicines
to help treat and protect people from HPV-associated diseases,
cancer and infectious diseases, today announced its inclusion in
the Russell 2000® Index
as part of the annual reconstitution of the Russell stock indexes. This reconstitution
became effective after the close of the US equities markets on
June 28, 2024.
"The last year has been transformational for INOVIO thanks to
our strategic vision focused on advancing late-stage candidates,
particularly our lead candidate INO-3107 for RRP," said INOVIO's
President and Chief Executive Officer, Dr. Jacqueline Shea. "Being readded to the
Russell 2000 signifies the value
of the progress we have made recently and our commitment to the
next level of our strategy, which includes our plans to submit a
BLA for INO-3107 under the FDA's accelerated approval pathway in
the second half of 2024 and preparing to be commercial launch-ready
in 2025, should INO-3107 be approved. We also continue to work to
advance other product candidates, including the next steps for
INO-3112 in head and neck cancer, INO-5401 in GBM, and INO-4201 as
an Ebola vaccine booster. We look forward to sharing our progress
on these and other programs as the year unfolds."
The annual reconstitution of the Russell US Indexes captures the
4,000 largest U.S. stocks as of April
30, ranking them by total market capitalization. Membership
in the Russell 3000®
Index, which remains in place for one year, means automatic
inclusion in either the large-cap Russell 1000® Index or the
small-cap Russell 2000®
Index, as well as the applicable growth and value style indexes.
FTSE Russell determines membership for its Russell indexes primarily by objective
market-capitalization rankings and style attributes.
Russell Indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. According to data as of the end of
December 2023, about $10.5 trillion in assets are benchmarked against
the Russell U.S. indexes, which belong to FTSE Russell, a prominent
global index provider.
For more information on the Russell 3000® Index and the
Russell indexes reconstitution,
visit the "Russell Reconstitution" section on the FTSE Russell
website.
About INOVIO
INOVIO is a biotechnology company focused
on developing and commercializing DNA medicines to help treat and
protect people from HPV-related diseases, cancer, and infectious
diseases. INOVIO's technology optimizes the design and delivery of
innovative DNA medicines that teach the body to manufacture its own
disease-fighting tools. For more information, visit
www.inovio.com.
About FTSE Russell
FTSE Russell is a leading global
provider of benchmarking, analytics, and data solutions for
investors, giving them a precise view of the market relevant to
their investment process. A comprehensive range of reliable and
accurate indexes provides investors worldwide with the tools they
require to measure and benchmark markets across asset classes,
styles, or strategies.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. For over 40 years,
leading asset owners, asset managers, ETF providers and investment
banks have chosen FTSE Russell indexes to benchmark their
investment performance and create ETFs, structured products, and
index-based derivatives.
FTSE Russell is focused on applying the highest industry
standards in index design and governance, employing transparent
rules-based methodology informed by independent committees of
leading market participants. FTSE Russell fully embraces the IOSCO
Principles, and its Statement of Compliance has received
independent assurance. Index innovation is driven by client needs
and customer partnerships, allowing FTSE Russell to continually
enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group. For
more information, visit
https://www.lseg.com/en/ftse-russell.
Contacts
Media: Jennie
Willson, (267) 429-8567, jennie.willson@inovio.com
Investors: Thomas Hong, (267) 440-4298,
thomas.hong@inovio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inovio-added-to-russell-2000-index-effective-july-1-2024-302186678.html
SOURCE INOVIO Pharmaceuticals, Inc.
